Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

Jose María Vieitez, Paula J. Fonseca, Jose P. Berros, Miguel Fernandez de Sanmamed, Eduardo Gutierrez Restrepo, Marta Izquierdo, Pablo Pardo, Angel J. Lacave

Abstract


The purpose of this prospective study was to assess the efficacy and safety of bevacizumab in combination with reduced doses of irinotecan plus capecitabine (CAPIRI regimen), in patients with metastatic colorectal cancer (mCRC), as first-line chemotherapy. A cohort of 120 mCRC consecutive patients was included. The overall response rate was 63.3% (76 patients; 95% confidence interval [CI], 53.97%-71.77%). Median time to progression and overall survival were 15 months (range: 2-49 months; 95% CI: 13.00, 17.00 months) and 22.5 months (range: 4-54 months; 95% CI: 21.00, 27.00 months), respectively. The one year survival rate was 81.5%. CAPIRI-related grade 3/4 adverse events included alopecia (29.2%) and diarrhoea (16.7%), which were manageable. Bevacizumab-related grade 3 hypertension was reported in 2 patients. One patient died due to treatment related adverse event, which was no bevacizumab-related. In conclusion, combination of bevacizumab plus CAPIRI is a feasible treatment which provides a clinical benefit as first-line treatment in chemonaïve patients with mCRC.


Full Text: PDF DOI: 10.5539/cco.v1n2p25

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Cancer and Clinical Oncology ISSN 1927-4858(Print) ISSN 1927-4866(Online)

Copyright © Canadian Center of Science and Education

To make sure that you can receive messages from us, please add the 'ccsenet.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.